Healthy Extracts Q3 Revenue Falls 33% to $619K; Going-Concern Doubt Reaffirmed
HYEX sits 68% above its 52-week low of $0.805.
Summary
Healthy Extracts posted a 33% revenue decline to $619,326 for Q3 2026 and a nine-month net loss of $1,931,870, with cash of only $143,267 against $9.17 million of current liabilities. The company reaffirmed going-concern doubt and disclosed a new $258,750 convertible note with a discounted conversion price.
Key Events · Earnings and Guidance · HYEX
-
Q3 Revenue Falls 33%
Net revenue was $619,326 for the three months ended September 30, 2026, down from $917,975 a year earlier; nine-month revenue rose 52% to $4,296,668 on the GummyUSA and Adli acquisitions.
-
Losses Widen, Costs Double
Nine-month net loss widened to $1,931,870 from $727,133, with general and administrative expense up 108% to $4,445,550.
-
Going-Concern Doubt Reaffirmed
Accumulated deficit reached $22,053,333 with cash of just $143,267 at September 30, 2026; management says it must keep raising debt and equity, which will likely be dilutive.
-
Current Liabilities Jump to $9.17M
Total current liabilities rose to $9,165,747 from $1,763,169 at December 31, 2025, driven by a $5,400,000 related-party stock loan and $6,379,724 of related-party notes payable.
Analysis · HYEX · Life Sciences
Revenue dropped 33% year over year to $619,326 while the nine-month net loss widened to $1,931,870 from $727,133, and general and administrative costs more than doubled to $4,445,550. The balance sheet is the bigger problem: cash sits at just $143,267 against $9,165,747 of current liabilities, up from $1,763,169 at year-end, largely because a $5,400,000 related-party stock loan and $6,379,724 of related-party notes now sit in current liabilities. Management repeats substantial doubt about continuing as a going concern and says it will keep raising debt and equity, which means more dilution for a company already carrying a $22,053,333 accumulated deficit. A new $258,750 convertible note issued July 17, 2026 converts at 75% of the lowest closing bid over the prior 15 days, so conversions can add shares below market.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HYEX was trading at $1.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $19.9M. The 52-week trading range was $0.81 to $4.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.